Versantis

Versantis is a Swiss pharmaceutical company developing new generations of liver disease medicines and diagnostics addressing high unmet medical needs.

[Versantis @VersantisAG]

We’re excited to announce that Versantis has agreed to be acquired by GENFIT. By combining forces our vision to revolutionize the care of patients suffering from #liverdisease will persist. Learn more about this transaction in the press release: https://t.co/ctDBWDfajF

[Versantis @VersantisAG]

A fresh start in the new year with a brand new identity!
Check out our new website: https://t.co/vpj06riG0X.
We are the same company with a new, vibrant and exciting face to the world. Our mission to transform the care of patients with #liverdisease continues.

[Versantis @VersantisAG]

Delighted to welcome Prof Dr Katharina Staufer to @VersantisAG as Chief Medical Officer. Katharina has a wealth of clinical and management experience in #liverdiseases. She is a great addition to our team as we advance #VS01 development on a global scale >>https://t.co/OnTjljGKuG

[startupticker @startuptickerCH]

Versantis' lead molecule has received a Rare Pediatric Diseases Designation from the U.S. FDA and an Orphan Drug Designation from EMA. Now U.S. Food and Drug Administration has also granted Versantis orphan drug designation to VS-01. https://t.co/gKc74GGFpV

[AGEFI Suisse @Ageficom]

La #biotech zurichoise @VersantisAG annonce que son traitement phare VS-01 a obtenu le statut de médicament orphelin de la part des autorités américaines ⬇ https://t.co/6mgOk5xfnI

[Versantis @VersantisAG]

FDA grants Orphan Drug Designation for #VS01 for the treatment of #hyperammonemia in Inborn Errors of Metabolism. This second #ODD from FDA is a significant milestone for the development of VS-01 and a strong recognition of its clinical potential.
https://t.co/OnTjljGKuG

[Versantis @VersantisAG]

Today is #WorldHepatitisDay! With a person dying every 30s from a hepatitis-related illness and over 350M people living with it globally, we must raise awareness now. Hepatitis is the primary underlying disease of #ACLF, an underserved syndrome we can’t wait to support with #VS01

[Versantis @VersantisAG]

Sadly, England witnessed a staggering 21% surge in alcohol-related death in pandemic year. @LiverTrust says "We need urgent actions to avoid a liver disease epidemic in the future". #VS01 aims to support these patients by reversing cirrhosis complications. https://t.co/iDfgw6g081

[Urea Cycle Disorder @ureacyclerm]

Complications of having a urea cycle disorder:
When a person has too much ammonia in their blood (hyperammonemia), it can cause them to have a serious complication called a hyperammonemic crisis.
#UCD #UreaCycleDisorder #UreaCycle https://t.co/VYdQRFZjl0

[Versantis @VersantisAG]

Why are #UCD and neonatal #hyperammonemia so hard to control? Great summary added to @RaremarkHealth knowledge bank. Delayed diagnosis and access to emergency treatments increase risks of long-lasting brain damages. We aim to solve this situation with #VS01.

[Urea Cycle Disorder @ureacyclerm]

Why are urea cycle disorders (UCDs) so hard to control?
UCDs are complex. Their main complication is #hyperammonemia, which means that high levels of ammonia are in your blood. Find out more in our article. #UCD #OTCD https://t.co/qw6fEsVxTF

[Versantis @VersantisAG]

Hi Leo! We'd like to officially welcome Leo Hofmann to the @VersantisAG team. Leo brings a wealth of pharmaceutical technology expertise to support the development of our pipeline products and R&D projects. We are excited to have him on board!

[Versantis @VersantisAG]

Today marks International #NASHday. NASH is a life-threatening liver disease rapidly becoming the dominant driver for #cirrhosis and liver transplantations. At Versantis, we aim to reverse multi-organ complications of cirrhosis with #VS01, our first-line liposome-based therapy.

[Versantis @VersantisAG]

Excited to attend #BIODigital next week. Join us to see our fresh clinical data and understand how we can transform the care of #liverdiseases! Interested in hearing more? Contact us on [email protected].
https://t.co/lVRBYWEldM

[Versantis @VersantisAG]

Check out this new paper from #MDPIPharmaceutics revealing the potential of #liposomes to enhance #dialysis and augment the removal of intoxicants. We are proud to be pioneering this new field and to open avenues for the clinical use of liposomes. https://t.co/vGEBvON851

[Versantis @VersantisAG]

A huge THANK YOU goes to Prof Dr J Trebicka and the clinical team at the Goethe University Hospital Frankfurt! 👏👏

[Versantis @VersantisAG]

Excited to announce positive results from our Phase 1b clinical trial of VS-01 in decompensated #livercirrhosis. Data show excellent tolerability and improvements in selected biomarkers after multiple-dose treatment. Press release: https://t.co/OnTjljGKuG

[Venturelab @venturelab_ch]

"The most rewarding aspect of being a founder is to start writing the story of your startup on a blank page"
Meriam Kabbaj, COO of TOP 100 Swiss Startup @VersantisAG, reflecting on routines, books, family, and more.
Get inspired: https://t.co/duZoWIJw0d
#SwissStartups #TOP100SSU

[Versantis @VersantisAG]

@VersantisAG appoints seasoned pharma executive and experienced deal-maker Chris Seaton to its Board. Very excited to working with him on building out our pipeline business development strategy. Full press release: https://t.co/OnTjljGKuG

[Versantis @VersantisAG]

Our most recent scientific publication on VS-01 and its non-clinical development now available online. Enjoy reading!

[J Controlled Release @JCRnEDITORS]

Preclinical evaluation of liposome-supported peritoneal dialysis for the treatment of hyperammonemic crises.
| Jean-Christophe Leroux, ETH Zurich | @MatooriSimon @ETH_en @VersantisAG
https://t.co/KPJX6lQG7X

[Versantis @VersantisAG]

US #FDA grants Rare Pediatric Disease Designation to VS-01, a potentially life-saving therapy for children with urea cycle disorders. A major milestone to kick-off our pediatric development program. Check our our press release: https://t.co/VqO4nRv8rf